{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T04:55:04Z","timestamp":1755838504641},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Sanofi- Aventis GmbH, Berlin, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00592-016-0862-0","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T07:45:32Z","timestamp":1461051932000},"page":"717-726","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin"],"prefix":"10.1007","volume":"53","author":[{"given":"Albrecht","family":"Fiesselmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"issue":"21","key":"862_CR1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC et al (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281(21):2005\u20132012","journal-title":"JAMA"},{"issue":"Suppl 1","key":"862_CR2","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/dc16-S010","volume":"39","author":"American Diabetes, A","year":"2016","unstructured":"American Diabetes, A (2016) 7. Approaches to glycemic treatment. Diabetes Care 39(Suppl 1):S52\u2013S59","journal-title":"Diabetes Care"},{"issue":"9","key":"862_CR3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1055\/s-0029-1239559","volume":"117","author":"S Matthaei","year":"2009","unstructured":"Matthaei S et al (2009) Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 117(9):522\u2013557","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"862_CR4","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/dc13-2743","volume":"37","author":"P Home","year":"2014","unstructured":"Home P et al (2014) Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 37(6):1499\u20131508","journal-title":"Diabetes Care"},{"issue":"17","key":"862_CR5","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","volume":"357","author":"RR Holman","year":"2007","unstructured":"Holman RR et al (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357(17):1716\u20131730","journal-title":"N Engl J Med"},{"issue":"4","key":"862_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00592-014-0698-4","volume":"52","author":"P Rys","year":"2015","unstructured":"Rys P et al (2015) Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 52(4):649\u2013662","journal-title":"Acta Diabetol"},{"issue":"1","key":"862_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00592-015-0732-1","volume":"53","author":"M Monami","year":"2016","unstructured":"Monami M et al (2016) Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetol 53(1):35\u201340","journal-title":"Acta Diabetol"},{"issue":"4","key":"862_CR8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00592-008-0052-9","volume":"45","author":"MA Baxter","year":"2008","unstructured":"Baxter MA (2008) The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Acta Diabetol 45(4):253\u2013268","journal-title":"Acta Diabetol"},{"issue":"8","key":"862_CR9","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/diacare.23.8.1130","volume":"23","author":"H Yki-Jarvinen","year":"2000","unstructured":"Yki-Jarvinen H et al (2000) Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901\/3002 Study Group. Diabetes Care 23(8):1130\u20131136","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"862_CR10","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1002\/dmrr.304","volume":"18","author":"H Yki-Jarvinen","year":"2002","unstructured":"Yki-Jarvinen H (2002) Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 18(Suppl 3):S77\u2013S81","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"862_CR11","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.clinthera.2007.08.020","volume":"29","author":"P Mullins","year":"2007","unstructured":"Mullins P et al (2007) Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 29(8):1607\u20131619","journal-title":"Clin Ther"},{"issue":"4","key":"862_CR12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2337\/diacare.28.4.950","volume":"28","author":"J Rosenstock","year":"2005","unstructured":"Rosenstock J et al (2005) Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28(4):950\u2013955","journal-title":"Diabetes Care"},{"issue":"1","key":"862_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/11319510-000000000-00000","volume":"3","author":"J Moock","year":"2010","unstructured":"Moock J et al (2010) Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ). Patient 3(1):45\u201358","journal-title":"Patient"},{"issue":"3","key":"862_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2003-39080","volume":"35","author":"M Massi Benedetti","year":"2003","unstructured":"Massi Benedetti M et al (2003) A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35(3):189\u2013196","journal-title":"Horm Metab Res"},{"issue":"12","key":"862_CR15","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","volume":"138","author":"A Fritsche","year":"2003","unstructured":"Fritsche A, Schweitzer MA, Haring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138(12):952\u2013959","journal-title":"Ann Intern Med"},{"issue":"1","key":"862_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1532-5415.2011.03773.x","volume":"60","author":"P Lee","year":"2012","unstructured":"Lee P et al (2012) Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. J Am Geriatr Soc 60(1):51\u201359","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"862_CR17","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26(11):3080\u20133086","journal-title":"Diabetes Care"},{"issue":"3","key":"862_CR18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","volume":"49","author":"H Yki-Jarvinen","year":"2006","unstructured":"Yki-Jarvinen H et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49(3):442\u2013451","journal-title":"Diabetologia"},{"issue":"4","key":"862_CR19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","volume":"37","author":"FG Eliaschewitz","year":"2006","unstructured":"Eliaschewitz FG et al (2006) Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 37(4):495\u2013501","journal-title":"Arch Med Res"},{"issue":"12","key":"862_CR20","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/diabetes.49.12.2142","volume":"49","author":"M Lepore","year":"2000","unstructured":"Lepore M et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49(12):2142\u20132148","journal-title":"Diabetes"},{"issue":"5","key":"862_CR21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diacare.23.5.644","volume":"23","author":"L Heinemann","year":"2000","unstructured":"Heinemann L et al (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23(5):644\u2013649","journal-title":"Diabetes Care"},{"issue":"10","key":"862_CR22","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1210\/jc.2007-2871","volume":"93","author":"T Linn","year":"2008","unstructured":"Linn T et al (2008) Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. J Clin Endocrinol Metab 93(10):3839\u20133846","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"862_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1463-1326.2011.01469.x","volume":"14","author":"CJ Currie","year":"2012","unstructured":"Currie CJ, Johnson JA (2012) The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 14(1):1\u20134","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"862_CR24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/dc10-1710","volume":"34","author":"D Giugliano","year":"2011","unstructured":"Giugliano D et al (2011) Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7\u00a0% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 34(2):510\u2013517","journal-title":"Diabetes Care"},{"issue":"6","key":"862_CR25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","volume":"29","author":"K Hermansen","year":"2006","unstructured":"Hermansen K et al (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29(6):1269\u20131274","journal-title":"Diabetes Care"},{"issue":"4","key":"862_CR26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"OT Investigators","year":"2012","unstructured":"Investigators OT et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319\u2013328","journal-title":"N Engl J Med"},{"issue":"11","key":"862_CR27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1463-1326.2011.01433.x","volume":"13","author":"AE Pontiroli","year":"2011","unstructured":"Pontiroli AE, Miele L, Morabito A (2011) Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 13(11):1008\u20131019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"862_CR28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11883-016-0568-3","volume":"18","author":"LI Igel","year":"2016","unstructured":"Igel LI et al (2016) Metformin: an old therapy that deserves a new indication for the treatment of obesity. Curr Atheroscler Rep 18(4):16","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"862_CR29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/dom.12214","volume":"16","author":"W Polonsky","year":"2014","unstructured":"Polonsky W et al (2014) More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 16(3):255\u2013261","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"862_CR30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00592-014-0591-1","volume":"51","author":"G Petrovski","year":"2014","unstructured":"Petrovski G et al (2014) Successful desensitization in patient with type 2 diabetes with an insulin allergy using insulin pump and glargine. Acta Diabetol 51(6):1073\u20131075","journal-title":"Acta Diabetol"},{"issue":"4","key":"862_CR31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00592-014-0707-7","volume":"52","author":"E Succurro","year":"2015","unstructured":"Succurro E et al (2015) Bilateral lower limbs edema with \u201cwooden\u201d character induced by insulin glargine treatment. Acta Diabetol 52(4):809\u2013811","journal-title":"Acta Diabetol"},{"key":"862_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-015-0797-x","author":"D Iafusco","year":"2015","unstructured":"Iafusco D et al (2015) Lower limbs edema by insulin glargine treatment: two other cases in pediatrics. Acta Diabetol. doi: 10.1007\/s00592-015-0797-x","journal-title":"Acta Diabetol"},{"issue":"3","key":"862_CR33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/193229681000400302","volume":"4","author":"JL Selam","year":"2010","unstructured":"Selam JL (2010) Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 4(3):505\u2013513","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"862_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/193229680800200221","volume":"2","author":"E Asamoah","year":"2008","unstructured":"Asamoah E (2008) Insulin pen-the \u201ciPod\u201d for insulin delivery (why pen wins over syringe). J Diabetes Sci Technol 2(2):292\u2013296","journal-title":"J Diabetes Sci Technol"},{"issue":"11","key":"862_CR35","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/S0149-2918(03)80337-5","volume":"25","author":"M Korytkowski","year":"2003","unstructured":"Korytkowski M et al (2003) A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial\/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 25(11):2836\u20132848","journal-title":"Clin Ther"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-016-0862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-016-0862-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-016-0862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-016-0862-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T02:51:36Z","timestamp":1655520696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-016-0862-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s00592-016-0862-0","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,19]]}}}